anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study utilized intelligent devices to remotely monitor patients with chronic obstructive pulmonary disease (COPD), aiming to construct and evaluate machine learning (ML) models that predict the probability of acute exacerbations of COPD (AECOPD).
METHODS: Patients diagnosed with COPD Group C/D at our hospital between March 2019 and June 2021 were enrolled in this study. The diagnosis of COPD Group C/D and AECOPD was based on the GOLD 2018 guidelines. We developed a series of machine learning (ML)-based models, including XGBoost, LightGBM, and CatBoost, to predict AECOPD events. These models utilized data collected from portable spirometers and electronic stethoscopes within a five-day time window. The area under the ROC curve (AUC) was used to assess the effectiveness of the models.
RESULTS: A total of 66 patients were enrolled in COPD groups C/D, with 32 in group C and 34 in group D. Using observational data within a five-day time window, the ML models effectively predict AECOPD events, achieving high AUC scores. Among these models, the CatBoost model exhibited superior performance, boasting the highest AUC score (0.9721, 95 % CI: 0.9623-0.9810). Notably, the boosting tree methods significantly outperformed the time-series based methods, thanks to our feature engineering efforts. A post-hoc analysis of the CatBoost model reveals that features extracted from the electronic stethoscope (e.g., max/min vibration energy) hold more importance than those from the portable spirometer.
CONCLUSIONS: The tree-based boosting models prove to be effective in predicting AECOPD events in our study. Consequently, these models have the potential to enhance remote monitoring, enable early risk assessment, and inform treatment decisions for homebound patients with chronic COPD.
Use of somatostatin (I), or its agonistic analogs (Ia), to prepare a composition for regulating the ovarian follicular reserve in non-menopausal women, especially to reduce exhaustion of the reserve over time. An independent claim is also included for use of an antagonistic analog (Ib) of somatostatin to prepare a composition for accelerating entry of quiescent follicles into growth, in non-menopausal women. ACTIVITY : Gynecological; Antiinfertility; Dermatological; Osteopathic. MECHANISM OF ACTION : Somatostatin agonist; Somatostatin antagonist. Fragments of ovine ovarian cortex were cultured under 5% carbon dioxide, in nutrient medium, and after 10 days only about 10% of the follicles were in the quiescent state while about 65% had developed into primary follicles. When the test was repeated in presence of 10 -6> M somatostatin, about 65% were still quiescent after 10 days and about 15% had developed into primary follicles.
Corpuscles for implantation into or at body tissue have carriers of biologically inert material, and such carriers contain medicine which is distributed therein for release into body tissue upon completion of the implanting operation. The configuration of the carriers departs from a spherical or an exact spheroidal shape. The end sections of the carriers can have conical, frustoconical, semiellipsoidal, or semispherical shapes and can consist of pairs of identical or different segments. The central sections of the carriers can resemble barrels, or their central longitudinal cross sections can have conical, elliptical, straight or other outlines. The carriers have central or substantially central longitudinal passages for a filament which supports a surgically implantable composition constituting a row or file or string of two or more identical and/or different carriers. The transverse cross sections of the carriers can have circular, elliptical, polygonal and/or other outlines. An advantage of the corpuscles is that the surface-to-volume ratio of their carriers is more satisfactory than that of the carriers forming part of conventional corpuscles so that they can be readily withdrawn from the body.
The present invention provides a respiratory monitoring device and a clinic bed for monitoring respiratory state of a patient. The device includes a first Doppler sensor, an amplification circuit, a filtering circuit, and a controller. The first Doppler sensor located on a first side guardrail of the clinic bed for sensing a respiratory state of the patient and outputting a first sensing signal. The amplification circuit coupled to the first Doppler sensor for amplifying the first sensing signal; and the filtering circuit filters the amplified first sensing signal, and outputs first signal. The controller receives the first signal and determines whether the patient has breathing according to the first signal, and output a patient abnormal signal to notify a caregiver when it is determined that the patient is not breathing. So that the non-contact detection of the human physiological signals can be realized, and the restriction and discomfort feeling of traditional contact type detection equipment to the patient can be avoided.
Non-ambulatory nursing home residents \>= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
FIELD: organic chemistry. SUBSTANCE: invention relates to derivatives of decahydroisoquinoline of the formula (I) given in description exhibiting activity of antagonist of receptors of amino acid-mediating agent of excitement. Synthesized compounds can be used in medicine. Invention relates to pharmaceutical composition based on the compounds synthesized also. EFFECT: improved method of synthesis, enhanced effectiveness of compounds synthesized. 8 cl, 3 tbl, 26 ex
This arm is a daily treatment regimen of a placebo with a loading dose and a daily dose of placebo capsules to match the treatment arms. Placebo regimen will run concurrently with treatment with IV amikacin. Placebo regimen will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
PCT No. PCT/AU88/00485 Sec. 371 Date Aug. 24, 1989 Sec. 102(e) Date Aug. 24, 1989 PCT Filed Dec. 20, 1988 PCT Pub. No. WO89/05822 PCT Pub. Date Jun. 29, 1989.Peptide analogues of insulin-like growth factor 1 and growth factor 2 are disclosed. When the analogue is an analogue of growth factor 1 the glutamic acid residue is absent from position 3 of the N-terminal and either the glutamic acid residue or the threonine residue adjacent to glutamic acid residue at position 3 is replaced by a different amino acid residue. When the peptide analogue is an analogue of insulin growth factor 2 the glutamic acid residue position 5 is absent. Preferred peptide analogues are disclosed. Methods of use in pharmaceutical and veterinary preparations are described.
Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.
PROBLEM TO BE SOLVED: To provide a dental gypsum investment composition capable of keeping a stable performance without removing fine particles caused by a pneumatic transportation at the time of producing and being used for the casting of a high m.p. alloy such as an alloy for baking ceramics, and having excellent heat resistance. SOLUTION: This composition is obtained by mixing 0.01-1.0 pts.wt. of tetrafluoro-ethylene resin with 100 pts.wt. of a mixed material composed of α-hemihydrate gypsum as a binder, qualtz and/or cristobalite as a refractory material and one or more kinds selected among groups consisting of metallic oxide, metallic carbide and metallic nitride as an aggregate which may be replaced of a part of the refractory, and further mixing 0.01-0.05 pts.wt. of anion surfactant of one or more kinds selected among groups consisting of alkylbenzene sulfonate and alkyl sulfate thereinto.
Mandibular repositioning appliances for the treatment of snoring and sleep apneas are increasingly used over the world, although the number of prescriptions of this therapy varies between countries. The appliance widens the upper airways during sleep in order to reduce sleep-disordered breathing. The device is easy to use and has become popular among patients. Despite this, the evidence for effects of this treatment is not very strong and based on only a few studies. The aim of this study is therefore to test the hypothesis that a mandibular repositioning appliance reduces sleep apneas, daytime sleepiness and other sleep apnea symptoms and increases the quality of life in sleepy patients with mild to moderate obstructive sleep apnea and in patients with symptomatic snoring. Secondary outcomes include effects on headaches, blood pressure and markers of stress, inflammation, cardiovascular health and oxidative stress. At baseline and after 4 month's treatment, the patients will respond to questionnaires about symptoms and quality of life. They will undergo measurements of sleepiness, sleep apneas and blood pressure as well as sampling of saliva, urine and blood. Factors that predict a successful treatment outcome will be analyzed in order to more exactly clarify the indications for this treatment modality in a group of patients who have been suggested to benefit from mandibular repositioning appliances according to previous studies and reviews.
PROBLEM TO BE SOLVED: To provide an oral composition which can be continuously ingested in a safe way, and also has a high effect of improving excessive cold sensitivity.SOLUTION: The oral composition includes the extract of Indian long pepper and the extract of angelica in (1:0.01) to (1:0.5) by a (weight) ratio expressed in terms of dried products. In the oral composition, the (weight) ratio between the extract of Indian long pepper and the extract of angelica expressed in terms of dried products is (1:0.02) to (1:0.3). The agent for improving feeling of cold includes any one of the oral compositions as an active constituent. The agent for inhibiting a chilly feeling after a bath includes any one of the oral compositions as an active constituent. In the method for inhibiting a chilly feeling after a bath, any one of the oral compositions is ingested from a time before two hours of bath start to a time when bathing. The food and drink include any one of the oral compositions.
Although laparoscopic sacrocolpopexy (LscASC) has been demonstrated to yield comparable success rates to abdominal sacrocolpopexy (93-99%) for the surgical treatment of pelvic organ prolapse, it has not been widely adopted due to the increased operating time and steep learning curves associated with laparoscopic suturing and knot-tying. For these reasons, robotic systems have been advocated for this technique. The objective of this study is to conduct a prospective single-blinded randomized controlled trial of robotic assisted versus traditional LscASC in the treatment of patients with apical vaginal prolapse stages II-IV (prolapse from 1 cm proximal to the hymen to all points distal).

This is a prospective single-blinded randomized controlled trial. Robotic assisted LscASC will be performed using the da Vinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) in a similar manner as that described above for conventional laparoscopy. Data points recorded during the procedure will include: operating room time of entry and exit, time from incision to closure and time taken for the suturing aspect of the case. From this information, the operating room costs and anesthesia costs, i.e., the amount that a provider must pay for goods or services, will be calculated. Estimated blood loss, perioperative and post-operative complications, and number of days in the hospital will be studied as will cost-effectiveness and impact on HRQOL
Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
Obesity has become a global issue that affects the emergence of various chronic diseases such as diabetes mellitus, dysplasia, heart disorders, and cancer. In this study, an integration method was developed between the metabolite profile of the active compound of Murraya paniculata and the exploration of the targeting mechanism of adipose tissue using network pharmacology, molecular docking, molecular dynamics simulation, and in vitro tests. Network pharmacology results obtained with the skyline query technique using a block-nested loop (BNL) showed that histone acetyltransferase p300 (EP300), peroxisome proliferator-activated receptor gamma (PPARG), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) are potential targets for treating obesity. Enrichment analysis of these three proteins revealed their association with obesity, thermogenesis, energy metabolism, adipocytokines, fat cell differentiation, and glucose homeostasis. Metabolite profiling of M. paniculata leaves revealed sixteen active compounds, ten of which were selected for molecular docking based on drug-likeness and ADME results. Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. The stability of the protein-ligand complex resulting from docking was examined using molecular dynamics simulations, and we observed the best average root mean square deviation (RMSD) of 0.99 Å for PPARG with trans-3-indoleacrylic acid, which was lower than with the native ligand BRL (2.02 Å). Furthermore, the RMSD was 2.70 Å for EP300 and the native ligand 99E, and the lowest RMSD with the ligand (1R,9S)-5-[(E)-2-(4-Chlorophenyl)vinyl]-11-(5-pyrimidinylcarbonyl)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one was 3.33 Å. The in vitro tests to validate the potential of M. paniculata in treating obesity showed that there was a significant decrease in PPARG and EP300 gene expressions in 3T3-L1 mature adipocytes treated with M. paniculata ethanolic extract starting at concentrations 62.5 μg/ml and 15.625 μg/ml, respectively. These results indicate that M. paniculata can potentially treat obesity by disrupting adipocyte maturation and influencing intracellular lipid metabolism.
All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
The invention discloses a traditional Chinese medicine drug which cures lupus erythematosus. The invention is characterized in that: the invention is a soup granule produced by materials in the following weight rate: 30g of caulis lonicerae, 15g of forsythia, 30g of dandelion, 30g of dyers woad leaf, 20g of radix isatidis, 10g of gromwell, 15g of Herba Houttuyniae, 10g of violet, 10g of angelica, 10g of red peony root and 15g of fresh rehmannia root. The invention chooses purely natural raw materials related to the traditional Chinese medicine, wherein, each component accords with the provisions of medicinal laws, making use of the comprehensive effect of the traditional Chinese medicine. Having effects on the lupus erythematosus, the invention has no chemical sweetening agent and has no toxicum as well as harm to human body. The medicine in the invention is a little sweet in taste without bitterness and easy for being taken. Being proven in cases in clinical observation, five days is one curative period, and two times per day while 50ml per time. A patient is healed generally after three curative periods. So far, the invention is effective for nearly 1000 cases of patients, and the total effectiveness rate is 100 percent.
The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.
Osteoarthritis is the most common disorders of the joints, which gives a page more than 10% of the world population aged over 45 years (Woolf A. D., Pfleger B., Bergman S., 2009). The main clinical manifestations of the disease are pain in the joints and a violation of their functions. Therefore, one of the first tasks in the therapeutic program, these patients will decrease and possible pain relief. Nesteroi dnye anti-inflammatory drugs (NSAIDs) are the main group of medicines drugs used in medical practice in lech th Research Institute of pain in patients with lesions of the musculoskeletal system. The basis of the therapeutic effect of the second of these drugs is the suppression of the activity of Fe p IU NTA cyclooxygenase (COX). Prichё m, the suppression of the activity of COX-2 isoenzyme involved in the synthesis of prostaglandins, induce the development of pain and PLAYBACK tion and provides anti-inflammatory effects of NSAIDs. B Blocking out of the enzyme COX-1, which controls the synthesis of prostaglandins, have cited a protective properties, leading to side effects of NSAIDs These so called nye formed the basis for the creation of new NSAIDs that can selectively inhibit COX-2 and m and mally affect COX. - 1.

Nimesulide is a selective inhibitor of cyclooxygenase -2 vnym with Sat and anced analgesic and anti-inflammatory effect, but also has antibradikinin, antihistamine and antioxidant activity of Stu(Nasonov EL, 1999, 2001).
Pressure overload-induced cardiac hypertrophy is a common cause of heart failure (HF), and emerging evidence suggests that excessive oxidized lipids have a detrimental effect on cardiomyocytes. However, the key regulator of lipid toxicity in cardiomyocytes during this pathological process remains unknown. Here, we used lipidomics profiling and RNA-seq analysis and found that phosphatidylethanolamines (PEs) and Acsl4 expression are significantly increased in mice with transverse aortic constriction (TAC)-induced HF compared to sham-operated mice. In addition, we found that overexpressing Acsl4 in cardiomyocytes exacerbates pressure overload‒induced cardiac dysfunction via ferroptosis. Notably, both pharmacological inhibition and genetic deletion of Acsl4 significantly reduced left ventricular chamber size and improved cardiac function in mice with TAC-induced HF. Moreover, silencing Acsl4 expression in cultured neonatal rat ventricular myocytes was sufficient to inhibit hypertrophic stimulus‒induced cell growth. Mechanistically, we found that Acsl4-dependent ferroptosis activates the pyroptotic signaling pathway, which leads to increased production of the proinflammatory cytokine IL-1β, and neutralizing IL-1β improved cardiac function in Acsl4 transgenic mice following TAC. These results indicate that ACSL4 plays an essential role in the heart during pressure overload‒induced cardiac remodeling via ferroptosis-induced pyroptotic signaling. Together, these findings provide compelling evidence that targeting the ACSL4-ferroptosis-pyroptotic signaling cascade may provide a promising therapeutic strategy for preventing heart failure.
Pain perception arises from the integration of prior expectations with sensory information. Although recent work has demonstrated that treatment expectancy effects (e.g., placebo hypoalgesia) can be explained by a Bayesian integration framework incorporating the precision level of expectations and sensory inputs, the key factor modulating this integration in stimulus expectancy-induced pain modulation remains unclear. In a stimulus expectancy paradigm combining emotion regulation in healthy male and female adults, we found that participants' voluntary reduction in anticipatory anxiety and pleasantness monotonically reduced the magnitude of pain modulation by negative and positive expectations, respectively, indicating a role of emotion. For both types of expectations, Bayesian model comparisons confirmed that an integration model using the respective emotion of expectations and sensory inputs explained stimulus expectancy effects on pain better than using their respective precision. For negative expectations, the role of anxiety is further supported by our fMRI findings that (1) functional coupling within anxiety-processing brain regions (amygdala and anterior cingulate) reflected the integration of expectations with sensory inputs and (2) anxiety appeared to impair the updating of expectations via suppressed prediction error signals in the anterior cingulate, thus perpetuating negative expectancy effects. Regarding positive expectations, their integration with sensory inputs relied on the functional coupling within brain structures processing positive emotion and inhibiting threat responding (medial orbitofrontal cortex and hippocampus). In summary, different from treatment expectancy, pain modulation by stimulus expectancy emanates from emotion-modulated integration of beliefs with sensory evidence and inadequate belief updating.
FINTEPLA can cause somnolence, sedation, and lethargy. In controlled studies for DS (Study 1 and Study 2 combined), the incidence of somnolence, sedation, and lethargy was 25% in patients treated with FINTEPLA, compared with 11% of patients on placebo. In the controlled study for LGS (Study 3), the incidence of somnolence, sedation, and lethargy was 19% in patients treated with FINTEPLA, compared with 16% of patients on placebo. In general, these effects may diminish with continued treatment [see Adverse Reactions (6.1)].

Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on FINTEPLA to gauge whether it adversely affects their ability to drive or operate machinery.
Subjects with known Narcolepsy Type 1, under treatment at participating sleep clinics, will be recruited to Arm B. These subjects will be asked to withdraw from their Narcolepsy related medication therapy starting on day -7, undergo 1 week of at-home ambulatory monitoring with the Dreem Headband on days 1-7, and then undergo two consecutive nights of in-lab PSG followed by MSLT while synchronously using the Dreem headband.